INMBHealthcare · BiotechnologyThe 4 Wall Street analysts covering INmune Bio, Inc. hold a median 12-month price target of $7.5 — +226.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +226.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Mar 2026 | LUCID CAPITAL MARKETS | Upgrade | Buy | $2.00 → $9.00 |
| 2 July 2025 | Maxim Group | Maintains | Buy | — |
| 1 July 2025 | BTIG | Downgrade | Neutral | — |
| 1 July 2025 | Scotiabank | Downgrade | Sector Underperform | — |
| 13 Feb 2025 | Maxim Group | Maintains | Buy | — |
| 11 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 21 Oct 2024 | Alliance Global Partners | Initiates | Buy | $20 |
| 27 Sept 2024 | Raymond James | Initiates | Outperform | $18 |
| 22 Aug 2024 | Scotiabank | Initiates | Sector Outperform | $22 |
| 1 June 2023 | Baird | Initiates | Outperform | — |
| 24 May 2022 | B. Riley Securities | Downgrade | Neutral | — |
| 24 May 2022 | BTIG | Maintains | Buy | — |
| 24 Jan 2022 | B. Riley Securities | Maintains | Buy | — |
| 21 Apr 2021 | B. Riley FBR | Initiates | Buy | — |
| 21 Apr 2021 | B. Riley Securities | Initiates | Buy | — |
| 25 Nov 2020 | BTIG | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 25 Nov 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INMB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 1% of US stocks
Cheaper than 34% of US stocks
Cheaper than 74% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
INmune Bio Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the company's financial results and management commentary for the quarter.
Why it matters — The earnings call transcript provides INMB watchers with direct insight into the company's quarterly performance and management's stated outlook.
In its Q2 earnings call, INmune Bio outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early fourth quarter of 2026. The company also reported a narrower second-quarter net loss and a cash runway extending into the second quarter of 2027.
Why it matters — The UK conditional approval filing timeline for Ebstrocel and the extended cash runway are key near-term milestones for investors tracking INmune Bio's regulatory progress and financial stability.
INmune Bio announced it received approximately $4.2 million in R&D cash rebates from Australia in July 2026, plus about $0.4 million from the United Kingdom in June 2026. The combined rebate proceeds exceeded the company's net cash used in operating activities for the second quarter.
Why it matters — The rebates strengthen INmune Bio's balance sheet and extend its cash runway as it advances CORDStrom (Ebstrocel) toward regulatory filings.
INmune Bio Inc. announced it will release its second quarter 2026 financial results and provide a corporate update on Thursday, August 6th, 2026. Management will host a conference call and webcast at 4:30 pm ET to discuss the results for the quarter ended June 30, 2026.
Why it matters — The financial results and corporate update will offer INMB watchers the latest information on the company's quarterly performance and strategic progress as a late-stage biotechnology company.
INmune Bio has established a Scientific Advisory Board comprising global experts in MSC clinical translation to support the late-stage development and expansion of its CORDStrom platform. The board will advise on the regulatory and clinical development of Ebstrocel and guide the expansion of CORDStrom product opportunities.
Why it matters — An INMB watcher would care because assembling a dedicated Scientific Advisory Board of clinical translation experts signals a strategic step toward advancing Ebstrocel through late-stage regulatory and clinical development.
The 4 Wall Street analysts covering INmune Bio, Inc. have a median 12-month price target of $7.5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering INmune Bio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 52 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, INmune Bio, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +226.1% from the last close, and Ticker Nerd's factor model ranks INmune Bio, Inc. 52 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
INmune Bio, Inc. returned -2.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript". INmune Bio Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the company's financial results and management commentary for the quarter.
Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system. The primary purpose of its research and development efforts is to create treatments that help in managing and potentially curing a range of conditions by targeting innate immune functions. This approach is significant in the medical field, particularly in autoimmune diseases, cancer, and neurodegenerative disorders, where the immune system's regulation can have profound impacts on disease progression and patient outcomes. By harnessing the body's own defense mechanisms, Inmune Bio Inc. aims to advance therapeutic solutions that are both effective and minimize adverse side effects. Operating in a rapidly evolving sector, the company holds an influential role in the biotechnology market, contributing to cutting-edge scientific advancements. By fostering collaborations with research institutions and leveraging its proprietary technologies, Inmune Bio Inc. continues to push the boundaries of immune-based treatments, offering hope for novel applications across different medical conditions.
CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com